Kymera Therapeutics, Inc.
KYMR
Rank in Stocks
#2249
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Share Price
$108.61
Last synced: 2026-10-19
Market Cap
$8.93B
Change (1 day)
3.65%
Change (1 year)
79.51%
Country
US
Trade Kymera Therapeutics, Inc. (KYMR)
Category
Healthcare
P/E ratio for Kymera Therapeutics, Inc. (KYMR)
P/E ratio as of October 2026 TTM: -32.87
According to Kymera Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -32.87. At the end of 2023 the company had a P/E ratio of -10.11.
P/E ratio history for Kymera Therapeutics, Inc. from 2018 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -32.87 | 143.67% |
| 2024 | -13.49 | 33.38% |
| 2023 | -10.11 | 14.04% |
| 2022 | -8.87 | -71.48% |
| 2021 | -31.09 | -50.54% |
| 2020 | -62.87 | 75.27% |
| 2019 | -35.87 | -48.01% |
| 2018 | -68.99 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | -187.56% |
US
|
|
| -28.36 | -13.73% |
US
|
|
| -24.57 | -25.26% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -192.27% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.